Institution
Copenhagen University Hospital
Healthcare•Copenhagen, Denmark•
About: Copenhagen University Hospital is a healthcare organization based out in Copenhagen, Denmark. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 11567 authors who have published 21538 publications receiving 789884 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.
11,809 citations
••
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Abstract: Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. Methods We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Results The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P = 0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P = 0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P = 0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes. Conclusions
5,547 citations
••
Gregory A. Roth1, Gregory A. Roth2, Degu Abate3, Kalkidan Hassen Abate4 +1025 more•Institutions (333)
TL;DR: Non-communicable diseases comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2).
5,211 citations
••
Auckland University of Technology1, Institute for Health Metrics and Evaluation2, National Institutes of Health3, Clinical Trial Service Unit4, Columbia University Medical Center5, University of Miami6, Washington State Institute for Public Policy7, Copenhagen University Hospital8, National University of Ireland, Galway9, National University of Singapore10, University of Auckland11, Capital Medical University12, Imperial College London13
TL;DR: Regional and country-specific estimates of stroke incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) lost by age group and country income level are calculated, to improve understanding of stroke determinants and burden worldwide.
3,127 citations
••
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1 +1050 more•Institutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.
2,910 citations
Authors
Showing all 11643 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kari Stefansson | 206 | 794 | 174819 |
Jens J. Holst | 160 | 1536 | 107858 |
Børge G. Nordestgaard | 147 | 1047 | 95530 |
Anne Tjønneland | 139 | 1345 | 91556 |
Rasmus Nielsen | 135 | 556 | 84898 |
Torben Jørgensen | 135 | 883 | 86822 |
Ian Ford | 134 | 678 | 85769 |
Bente Klarlund Pedersen | 134 | 689 | 72177 |
Henrik Kehlet | 130 | 1069 | 76338 |
Peter M. Elias | 127 | 581 | 49825 |
Niels E. Skakkebæk | 127 | 596 | 59925 |
Jes Olesen | 124 | 808 | 79687 |
James A. Russell | 124 | 1024 | 87929 |
Christos Pantelis | 120 | 723 | 56374 |
Torben Hansen | 120 | 1058 | 89876 |